Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Lantern Pharma Q2 EPS $(0.40) Beats $(0.48) Estimate

Author: Benzinga Newsdesk | August 13, 2025 03:36pm
Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.48) by 17.53 percent. This is a 13.04 percent increase over losses of $(0.46) per share from the same period last year.

Posted In: LTRN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist